SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    James R. Burton, Jacqueline G. O’Leary, Elizabeth C. Verna, Varun Saxena, Jennifer L. Dodge, Richard T. Stravitz, Joshua Levitsky, James F. Trotter, Gregory T. Everson, Robert S. Brown, Norah A. Terrault, A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy, Journal of Hepatology, 2014,

    CrossRef

  2. 2
    Eva Van den Eynde, Elena Ferrer, Daniel Podzamczer, Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir, AIDS, 2014, 28, 10, 1538

    CrossRef

  3. 3
    Jin-Ching Lee, Chin-Kai Tseng, Kung-Chia Young, Hung-Yu Sun, Shainn-Wei Wang, Wei-Chun Chen, Chun-Kuang Lin, Yu-Hsuan Wu, Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells, British Journal of Pharmacology, 2014, 171, 1
  4. 4
    Blaire E. Burman, Paul Y. Kwo, Kris V. Kowdley, Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity, Hepatology International, 2014, 8, 3, 352

    CrossRef

  5. 5
    Sarah Talavera Pons, Geraldine Lamblin, Anne Boyer, Valérie Sautou, Armand Abergel, Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?, European Journal of Clinical Pharmacology, 2014, 70, 7, 775

    CrossRef

  6. 6
    Sarah Tischer, Robert J. Fontana, Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting, Journal of Hepatology, 2014, 60, 4, 872

    CrossRef

  7. 7
    EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, Journal of Hepatology, 2014, 60, 2, 392

    CrossRef

  8. 8
    Xi Liu, Yawen Wang, Guanjun Zhang, Na Li, Qianqian Zhu, Hongyun Chang, Qunying Han, Yi Lv, Zhengwen Liu, Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients, International Journal of Antimicrobial Agents, 2014, 44, 2, 145

    CrossRef

  9. 9
    Jesús Ruiz Ramos, Irene Romero Hernández, Patricia Marrero Álvarez, María Remedios Marqués Miñana, María José Fernández Megía, José Luis Poveda Andrés, Experiencia en el manejo de inmunosupresores con los fármacos inhibidores de proteasa frente al virus de la hepatitis C, Gastroenterología y Hepatología, 2014,

    CrossRef

  10. 10
    F.-K. F. Cheng, D. M. Torres, S. A. Harrison, Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?, Journal of Viral Hepatitis, 2014, 21, 1
  11. 11
    K. P. Hammond, C. Nielsen, S. A. Linnebur, J. A. Langness, G. Ray, P. Maroni, J. J. Kiser, Priapism Induced by Boceprevir-CYP3A4 Inhibition and  -Adrenergic Blockade: Case Report, Clinical Infectious Diseases, 2014, 58, 1, e35

    CrossRef

  12. 12
    Kazuto Fukuda, Yasuharu Imai, Naoki Hiramatsu, Keiko Irishio, Takumi Igura, Yoshiyuki Sawai, Sachiyo Kogita, Yuki Makino, Rui Mizumoto, Yasushi Matsumoto, Masanori Nakahara, Sinichiro Zushi, Nobuyuki Kajiwara, Tsugiko Oze, Sumio Kawata, Norio Hayashi, Tetsuo Takehara, Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C, Hepatology Research, 2014, 44, 8
  13. 13
    Ezequiel Ridruejo, Safety of direct-acting antivirals in the treatment of chronic hepatitis C, Expert Opinion on Drug Safety, 2014, 13, 3, 307

    CrossRef

  14. 14
    Antonio Rivero-Juarez, Karin Neukam, Pablo Labarga, Angela Camacho, Juan Macias, Pablo Barreiro, Julián Torre-Cisneros, Juan A. Pineda, Vicente Soriano, Antonio Rivero, Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy, Journal of Infection, 2014, 68, 4, 372

    CrossRef

  15. 15
    Marina Kawaguchi-Suzuki, Reginald F. Frye, The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014, 34, 2
  16. 16
    Vincenza Conteduca, Domenico Sansonno, Sabino Russi, Fabio Pavone, Franco Dammacco, Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents, Journal of Infection, 2014, 68, 1, 1

    CrossRef

  17. 17
    Xinhui Chen, Lane R. Bushman, Kevin J. McAllister, Peter L. Anderson, Jennifer J. Kiser, Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its R-isomer in human plasma, Biomedical Chromatography, 2014, 28, 8
  18. 18
    Clara T. M. M. de Kanter, Joost P. H. Drenth, Joop E. Arends, Henk W. Reesink, Marc van der Valk, Robert J. de Knegt, David M. Burger, Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations, Clinical Pharmacokinetics, 2014, 53, 5, 409

    CrossRef

  19. 19
    Peter N. Morcos, Linda Chang, Rohit Kulkarni, Mylene Giraudon, Nancy Shulman, Barbara J. Brennan, Patrick F. Smith, Jonathan Q. Tran, A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail, European Journal of Clinical Pharmacology, 2013, 69, 11, 1939

    CrossRef

  20. 20
    Emerson Y. Chen, Seth N. Sclair, Frank Czul, Betty Apica, Perry Dubin, Paul Martin, William M. Lee, A Small Percentage of Patients With Hepatitis C Receive Triple Therapy With Boceprevir or Telaprevir, Clinical Gastroenterology and Hepatology, 2013, 11, 8, 1014

    CrossRef

  21. 21
    Todd H. Driver, Norah Terrault, Varun Saxena, Acute Hepatitis C in an HIV-Infected patient: A Case Report and Review of Literature, Journal of General Internal Medicine, 2013, 28, 5, 734

    CrossRef

  22. 22
    Raúl J. Andrade, Javier García-Samaniego, Aspectos bioquímicos y farmacológicos de telaprevir, Enfermedades Infecciosas y Microbiología Clínica, 2013, 31, 2

    CrossRef

  23. 23
    Yuria Fujita, Kohji Noguchi, Tomonori Suzuki, Kazuhiro Katayama, Yoshikazu Sugimoto, Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein, BMC Research Notes, 2013, 6, 1, 445

    CrossRef

  24. 24
    T. Jake Liang, Marc G. Ghany, Current and Future Therapies for Hepatitis C Virus Infection, New England Journal of Medicine, 2013, 368, 20, 1907

    CrossRef

  25. You have free access to this content25
    Audrey Coilly, Bruno Roche, Didier Samuel, Current management and perspectives for HCV recurrence after liver transplantation, Liver International, 2013, 33,
  26. 26
    Jennifer J. Kiser, Charles Flexner, Direct-Acting Antiviral Agents for Hepatitis C Virus Infection, Annual Review of Pharmacology and Toxicology, 2013, 53, 1, 427

    CrossRef

  27. 27
    S. Mauss, H. Klinker, Drug-Drug Interactions in the Treatment of HCV Among People Who Inject Drugs, Clinical Infectious Diseases, 2013, 57, suppl 2, S125

    CrossRef

  28. 28
    Thomayant Prueksaritanont, Xiaoyan Chu, Christopher Gibson, Donghui Cui, Ka Lai Yee, Jeanine Ballard, Tamara Cabalu, Jerome Hochman, Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective, The AAPS Journal, 2013, 15, 3, 629

    CrossRef

  29. 29
    Jennifer J. Kiser, James R. Burton, Gregory T. Everson, Drug–drug interactions during antiviral therapy for chronic hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 10, 596

    CrossRef

  30. 30
    Indira Brar, Dwayne Baxa, Norman Markowitz, HCV Enters the Twenty-First Century, Current Infectious Disease Reports, 2013, 15, 1, 52

    CrossRef

  31. 31
    Joshua W. Allen-Dicker, David A. Suskin, David A. Fessler, Iatrogenic Adrenal Insufficiency in a Patient Treated With Telaprevir and Topical Corticosteroids, Infectious Diseases in Clinical Practice, 2013, 21, 5, 330

    CrossRef

  32. 32
    J. Trofe-Clark, T.L. Lemonovich, Interactions Between Anti-Infective Agents and Immunosuppressants in Solid Organ Transplantation, American Journal of Transplantation, 2013, 13, s4
  33. 33
    James R. Burton, Gregory T. Everson, Management of the Transplant Recipient with Chronic Hepatitis C, Clinics in Liver Disease, 2013, 17, 1, 73

    CrossRef

  34. You have free access to this content34
    Benjamin Maasoumy, Michael P. Manns, Optimal treatment with boceprevir for chronic HCV infection, Liver International, 2013, 33,
  35. 35
    Lawrence Serfaty, Optimizing DAA management in daily practice, Digestive and Liver Disease, 2013, 45, S318

    CrossRef

  36. 36
    Manie Juneja, Rebekah Euliano, Rohit Satoskar, James H. Lewis, Polypharmacy and Comorbidity Are Associated with a Lower Early Virologic Response in Hepatitis C Patients Treated with First Generation Protease Inhibitor Triple Therapy: A Preliminary Analysis, Digestive Diseases and Sciences, 2013, 58, 11, 3348

    CrossRef

  37. 37
    J. H. Lewis, J. G. Stine, Review article: prescribing medications in patients with cirrhosis – a practical guide, Alimentary Pharmacology & Therapeutics, 2013, 37, 12
  38. 38
    Rosângela Teixeira, Yone de Almeida Nascimento, Déborah Crespo, Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions, The Brazilian Journal of Infectious Diseases, 2013, 17, 2, 194

    CrossRef

  39. 39
    Laura Milazzo, Felicia Stefania Falvella, Carlo Magni, Cristina Gervasoni, Anna Maria Peri, Dario Cattaneo, Spinello Antinori, Simone Vidale, Seizures in Patients with Chronic Hepatitis C Treated with NS3/4A Protease Inhibitors: Does Pharmacological Interaction Play a Role?, Pharmacology, 2013, 92, 5-6, 235

    CrossRef

  40. 40
    Eric Lawitz, Jay P Lalezari, Tarek Hassanein, Kris V Kowdley, Fred F Poordad, Aasim M Sheikh, Nezam H Afdhal, David E Bernstein, Edwin DeJesus, Bradley Freilich, David R Nelson, Douglas T Dieterich, Ira M Jacobson, Donald Jensen, Gary A Abrams, Jama M Darling, Maribel Rodriguez-Torres, K Rajender Reddy, Mark S Sulkowski, Natalie H Bzowej, Robert H Hyland, Hongmei Mo, Ming Lin, Michael Mader, Robert Hindes, Efsevia Albanis, William T Symonds, Michelle M Berrey, Andrew Muir, Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial, The Lancet Infectious Diseases, 2013, 13, 5, 401

    CrossRef

  41. 41
    Qianqian Zhu, Na Li, Qunying Han, Pingping Zhang, Cuiling Yang, Xiaoyan Zeng, Yanping Chen, Yi Lv, Xi Liu, Zhengwen Liu, Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis, Antiviral Research, 2013, 98, 3, 373

    CrossRef

  42. 42
    David Back, Laura Else, The importance of drug–drug interactions in the DAA era, Digestive and Liver Disease, 2013, 45, S343

    CrossRef

  43. 43
    Paul M. Trembling, Sudeep Tanwar, William M. Rosenberg, Geoffrey M. Dusheiko, Treatment decisions and contemporary versus pending treatments for hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 12, 713

    CrossRef

  44. You have free access to this content44
    K. Rajender Reddy, Gregory T. Everson, Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation, Hepatology, 2013, 58, 3
  45. 45
    Colleen M Wegzyn, David L Wyles, Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV), Current Opinion in Pharmacology, 2012, 12, 5, 556

    CrossRef

  46. 46
    Kai-Jye Lou, Closing time for HCV protease, Science-Business eXchange, 2012, 5, 40

    CrossRef

  47. 47
    Carrie L. Jennings, Kenneth E. Sherman, Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline, Current HIV/AIDS Reports, 2012, 9, 3, 231

    CrossRef

  48. 48
    Annett Kunze, Jörg Huwyler, Gian Camenisch, Heike Gutmann, Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters, Biochemical Pharmacology, 2012, 84, 8, 1096

    CrossRef

  49. 49
    Norah Terrault, Liver transplantation in the setting of chronic HCV, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 531

    CrossRef

  50. 50
    José Vicente Fernández-Montero, Vicente Soriano, Management of hepatitis C in HIV and/or HBV co-infected patients, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 517

    CrossRef

  51. 51
    Geoffrey W. McCaughan, New therapies against HCV: Expected risks and challenges associated with their use in the liver transplant setting, Journal of Hepatology, 2012, 57, 6, 1361

    CrossRef

  52. 52
    Erik De Clercq, The race for interferon-free HCV therapies: a snapshot by the spring of 2012, Reviews in Medical Virology, 2012, 22, 6
  53. 53
    Dae Won Jun, Treatment of chronic hepatitis C, Journal of the Korean Medical Association, 2012, 55, 11, 1113

    CrossRef

  54. 54
    Rafael Esteban, Maria Buti, Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 445

    CrossRef

  55. 55
    Emanuele Focà, Diego Ripamonti, Davide Motta, Carlo Torti, Unboosted Atazanavir for Treatment of HIV Infection, Drugs, 2012, 72, 9, 1161

    CrossRef

  56. 56
    Paolo A. Grossi, Update in HIV infection in organ transplantation, Current Opinion in Organ Transplantation, 2012, 17, 6, 586

    CrossRef

  57. 57
    Jacqueline G. O’Leary, Michael A. Neri, James F. Trotter, Gary L. Davis, Göran B. Klintmalm, Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined, Transplant International, 2012, 25, 8
  58. 58
    Philipp Thies, M. Schmid, F. Geisler, Wann doppelt, wann dreifach gegen HCV?, MMW - Fortschritte der Medizin, 2012, 154, 19, 59

    CrossRef